Immix Biopharma, Inc.

IMMXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1873835

Concept	FY2024	FY2023	FY2022	FY2021
Revenues	$20.0M	$20.0M	—	—
Research and Development Expense	$8.7M	$4.2M	$126.5K	$248.1K
Operating Expenses	$16.1M	$8.2M	$1.4M	$453.9K
Operating Income (Loss)	-$16.1M	-$8.2M	-$1.4M	-$453.9K
Interest Expense	—	$497.00	$179.9K	$102.0K
Nonoperating Income (Expense)	$572.0K	-$497.00	-$23.0M	-$676.5K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$15.6M	-$8.2M	-$24.4M	-$1.1M
Income Tax Expense (Benefit)	$26.4K	$10.3K	$6.0K	$17.5K
Net Income (Loss) Attributable to Parent	-$15.4M	-$8.2M

Concept	FY2024	FY2023	FY2022	FY2021
Assets	$19.9M	$14.9M	$18.2M	$539.6K
Assets, Current	$19.8M	$14.9M	$18.2M	$532.2K
Cash and Cash Equivalents, at Carrying Value	$17.5M	$13.4M	$17.6M	$391.1K
Liabilities	$3.7M	$1.7M	$202.0K	$5.3M
Liabilities, Current	$3.7M	$1.3M	$202.0K	$5.3M
Accounts Payable, Current	$1.4M	$143.1K	—	—
Stockholders' Equity Attributable to Parent	$16.4M	$13.2M	—	-$3.6M
Common Stock, Shares, Outstanding	$19.9M	$13.9M	$13.2M	$3.4M

Concept	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$11.4M	-$7.4M	-$1.6M	-$404.7K
Net Cash Provided by (Used in) Investing Activities	-$52.1K	-$52.1K	-$802.00	-$802.00
Net Cash Provided by (Used in) Financing Activities	$15.5M	$3.2M	$18.8M	$18.8M
Payments to Acquire Property, Plant, and Equipment	$52.1K	$52.1K	$802.00	$802.00
Payments for Repurchase of Common Stock	—	$100.0K	$100.0K	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)